Assessment of the treatment of chronic hepatitis C in the state of mato grosso, central Brazil

Memorias do Instituto Oswaldo Cruz

Volumn 107, Issue 2, 2012, Pages 117-123

  de Azevedo, Francisco Kennedy Scofoni Faleiros ^a   de Azevedo, Cassius Clay Scofoni Faleiros ^b   Souto, Francisco José Dutra ^a  

^a HOSPITAL UNIVERSITÁRIO JÚLIO MÜLLER   (Brazil)

^b Pronto Socorro Municipal de Várzea Grande ^*  (Brazil)

Author keywords

Chronic hepatitis c; Egylated interferon; Ibavirin; Onventional interferon; Sustained virological response; Treatment

Indexed keywords

HEPATITIS C VIRUS;

ANTIVIRUS AGENT; VIRUS RNA;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAZIL; DRUG COMBINATION; FEMALE; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; MALE; METHODOLOGY; MIDDLE AGED; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BRAZIL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84857966536     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Acras RN, Pedroso ML, Caum LC, Pisani JC, Amarante HM, Carmes ER 2004. The sustained response rates for chronic hepatitis C patients undergoing therapy with the several interferons and ribavarins supplied by Brazilian Health Ministry is comparable to those reported in the literature. Arq Gastroenterol 41: 3-9.
2. Almeida PR, Mattos AA, Amaral KM, Feltrin AA, Zamin P, Tovo CV, Picon PD 2009. Treatment of hepatitis C with peginterferon and ribavirin in a public health program. epatogastroenterology 56: 223-226.
3. Alves AV, Azevedo AP, Perin C, Ramos GZ, Brandão AB, Mattos AA, Almeida PR 2003. Tratamento de pacientes com hepatite crônica pelo vírus C com interferon alfa e ribavirina: a experiência da Secretaria de Saúde do Rio Grande do Sul. Arq Gastroenterol 40: 227-232.
4. Bedossa P, Poynard T 1996. An algorithm for the grading of activity in chronic hepatitis C. The Metavir Cooperative Study Group. Hepatology 24: 289-293.
5. Brandão C, Barone A, Carrilho F, Silva A, Patelli M, Caramori C, Focaccia R, Pereira L, Pedroso M, Tatsch F, Pessoa M, Pegasys Brazilian Study Group 2006. The results of a randomized trial looking at 24 weeks vs. 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1. J Viral Hepat 13: 552-559.
6. Brook G, Soriano V, Bergin C 2010. European guideline for the management of hepatitis B and C virus infections. Int J Std AIDS 21: 669-678.
7. Campiotto S, Pinho JR, Carrilho FJ, Silva LC, Souto FJ, Spinelli V, Pereira LM, Coelho HS, Silva AO, Fonseca JC, Rosa H, Lacet CM, Bernardini AP 2005. Geographic distribution of hepatitis C virus genotypes in Brazil. Braz J Med Biol Res 38: 41-49.
8. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer Jr HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, David H, Van Thiel V, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, The Hepatitis Interventional Therapy Group 1989. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter, randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 321: 1501-1506.
9. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trépo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J 1998. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 339: 1493-1499.
10. Figueiredo-Mendes C, Cardoso C, Brandão-Mello CE, Pinto PT, Castro EJ, Pernambuco CD, Cardoso AC, Rosales FL, Milagre DR, Reis DM 2003. Eficácia do tratamento da hepatite crônica C com interferon alfa-2a ou 2b e ribavirina entre pacientes de hospitais públicos da cidade do Rio de Janeiro. Gastroenterol Endosc Digest 22: 7.
11. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales Jr FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
12. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases 2009. Diagnosis, management and treatment of hepatitis C: an update. Hepatology 49: 1335-1374.
13. Gonçales Jr FL, Moma CA, Vigani AG, Angerami AF, Gonçales ES, Tozzo R, Pavan MH, Gonçales NS 2010. Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life? BMC Infect Dis 10: 212.
14. Gonçales Jr FL, Vigani A, Gonçales N, Barone AA, Araújo E, Focaccia R, Oliveira U, Coelho HS, Paixao J, Perez R, Lobato C, Weirich J, Rosa H, Borges A, Vila R, Corrêa-Giannella ML, Ferraz ML 2006. Weight-based combination therapy with peginterferon- 2b and ribavirin for naïve, relapser and non-responder patients with chronic hepatitis C. Braz J Infect Dis 10: 311-316.
15. Hadziyannis S.J, Sette J.H, Morgan T.R, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer Jr H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM, PEGASYS International Study Group 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355.
16. Kim WR 2002. The burden of hepatitis C in the United States. Hepatology 36: 30-34.
17. Mangia A, Dalgard O, Minerva N, Verbaan H, Bacca D, Ring-Larsen H, Copetti M, Carretta V, Piazzolla V, Cozzolongo R, Mottola L, Andriulli A 2010. Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha 2b and ribavirin. Aliment Pharmacol Ther 31: 1346-1353.
18. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa- 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358: 958-965.
19. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, Mc-Cone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, IDEAL Study Team 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 361: 580-593.
20. Parise E, Cheinquer H, Crespo D, Meirelles A, Martinelli A, Sette H, Brazilian Pegasys Cooperative Study Group 2006. Peginterferon alfa-2a plus ribavirin in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy. Braz J Infect Dis 1: 11-16.
21. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J 1998. Randomized trial of interpheron alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interpheron alpha 2b plus placebo for 48 weeks treatment of chronic infection with hepatitis C virus. Hepatitis Interventional Therapy Group. Lancet 352: 1426-1432.
22. Sherman M, Yoshida EM, Deschenes M, Krajden M, Bain VG, Peltekian K, Anderson F, Kaita K, Simonyi S, Balshaw R, Lee SS, Canadian Pegasys Study Group 2006. Peginterferon alfa-2a
23. (40 KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 352: 1631-1638.
24. Silva GF, Rodrigo RJ, Pardini MI, Corvino SM, Henriques RM, Peres MN, Silveira LV, Coelho KI 2007. Using pegylated interferon alfa-2b and ribavirin to treat chronic hepatitis patients infected with hepatitis C virus genotype 1: are nonresponders and relapsers different populations? Braz J Infec Dis 11: 554-560.
25. Thomas DL, Seeff LB 2005. Natural history of hepatitis C. Clin. Liver Dis 9: 383-398.
26. Vigani AG, Pavan MH, Tozzo R, Gonçales ES, Feltrin A, Fais VC, Lazarini MS, Gonçales NS, Gonçales Jr FL 2008. Comparative study of patients with chronic hepatitis C virus infection due to genotypes 1 and 3 referred for treatment in Southeast Brazil. BMC Infect Dis 8: 164.
27. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ 2000. Peginterferon alpha-2a in patients with chronic hepatitis C. N Engl J Med 343: 1666-1672.
28. Zoulin F, Haem J, Ahmed SS, Chossegros P, Habersetzer F, Chevallier M, Bailly F, Trépo C 1998. Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J Viral Hepat 20: 193-198.